A research team from the Johns Hopkins University School of Medicine has pioneered a new therapeutic strategy designed to combat rare and aggressive T-cell lymphocytic blood cancers, which often prove resistant to standard treatments.

Scientists at the Baltimore-based institution explained that conventional therapies typically destroy both cancerous and healthy T-cells, leaving patients vulnerable to life-threatening infections. The novel approach, however, leverages a subtle genetic distinction between healthy T-cells and their malignant counterparts. The innovative technique involves engineering a specialized antibody that selectively targets cancer cells expressing the TRBC2 receptor.